BGB-16673

BGB-16673 is an investigational new drug that is being evaluated by BeOne Medicines for the treatment of relapsed and refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and other lymphomas.

Uses your system voice; voice and rate in settings.

≈ 1 min read

Cite, export and learn8 citation formats · 8 exports · lesson and quiz

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

BGB-16673 is an investigational new drug that is being evaluated by BeOne Medicines for the treatment of relapsed and refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and other lymphomas. BGB-16673 is a proteolysis targeting chimera (PROTAC) that acts by using the ubiquitin-proteasome system to target Bruton's tyrosine kinase (BTK) for degradation.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1362666655 under CC BY-SA 4.0; modifications have been made.

Provenance

snapshot enwiki-001362666655 · captured 2026-07-05 · ledger · version history

Cite this page as: encyclopegia.org, “BGB-16673”, snapshot enwiki-001362666655. https://encyclopegia.org/a/bgb-16673

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.